JOHN KIRKWOOD to Melanoma, Experimental
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Melanoma, Experimental.
Connection Strength
0.252
-
LAG-3 and PD-1 synergize on CD8+ T?cells to drive T cell exhaustion and hinder autocrine IFN-?-dependent anti-tumor immunity. Cell. 2024 Aug 08; 187(16):4355-4372.e22.
Score: 0.059
-
Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding. Sci Immunol. 2020 07 17; 5(49).
Score: 0.044
-
Cytokine-based therapy for melanoma: pre-clinical studies. Forum (Genova). 2000 Jul-Sep; 10(3):204-26.
Score: 0.044
-
Tumor cell oxidative metabolism as a barrier to PD-1 blockade immunotherapy in melanoma. JCI Insight. 2019 03 07; 4(5).
Score: 0.040
-
Interferon-? Drives Treg Fragility to Promote Anti-tumor Immunity. Cell. 2017 Jun 01; 169(6):1130-1141.e11.
Score: 0.036
-
Spontaneous CD4+ T cell responses against TRAG-3 in patients with melanoma and breast cancers. J Immunol. 2006 Aug 15; 177(4):2717-27.
Score: 0.017
-
Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition of mitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis. Clin Cancer Res. 2001 Mar; 7(3 Suppl):974s-979s.
Score: 0.012